SCIENTIFIC BACKGROUND

AKT1, BRCA1, BRCA2, ERBB2, ERBB3, ESR1, MDM2, NF1, NTRK1, NTRK2, NTRK3, PIK3CA, PTEN

SCIENTIFIC BACKGROUND

The PARP inhibitor olaparib (Lynparza®) is currently approved by the European Medicine Agency as maintenance therapy in advanced/metastatic HER2-negative breast carcinoma after prior chemotherapy, provided the patients are carriers of a pathogenic/probable pathogenic germline variant in BRCA1 or BRCA2.

 

Currently, the indication for the diagnosis of BRCA1/2 germline variants in patients with statutory health insurance is only given in case of clinical suspicion of a hereditary disease (see indication criteria in case of suspected hereditary breast/ovarian carcinoma syndrome). Due to the urgency of the case, it is not always possible to take a detailed family history and to consult a geneticist as recommended by the GenDG. In many cases, the diagnosis may not be indicated because the indication criteria are not fulfilled.

 

For patients who do not meet the indication for a familial disease, it is therefore recommended to seek clarification from the insurance provider.

GENES
AKT1, BRCA1, BRCA2, ERBB2, ERBB3, ESR1, MDM2, NF1, NTRK1, NTRK2, NTRK3, PIK3CA, PTEN
How to order